{"id":799691,"date":"2025-01-10T18:52:08","date_gmt":"2025-01-10T23:52:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/"},"modified":"2025-01-10T18:52:08","modified_gmt":"2025-01-10T23:52:08","slug":"sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/","title":{"rendered":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen<\/b><\/p>\n<p class=\"bwalignc\"><i>No Shareholder Action Required at This Time<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSage Therapeutics, Inc. (Nasdaq: SAGE) (\u201cThe Company\u201d), today confirmed that Biogen Inc. (Nasdaq: BIIB) (\u201cBiogen\u201d) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.<\/p>\n<p>\nConsistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.<\/p>\n<p>\nThere is no guarantee that any transaction will result from Biogen\u2019s proposal. Sage\u2019s shareholders do not need to take any action at this time.<\/p>\n<p><b>About Sage Therapeutics<\/b><\/p>\n<p>\nSage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sagerx.com&amp;esheet=54176851&amp;newsitemid=20250110340262&amp;lan=en-US&amp;anchor=www.sagerx.com&amp;index=1&amp;md5=07237cc8e2d5f18e86900537f8ace44e\">www.sagerx.com<\/a> or engage with us on Facebook, LinkedIn, Instagram, and X.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250110340262\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250110340262\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Ashley Kaplowitz<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Ashley.Kaplowitz@sagerx.com\">Ashley.Kaplowitz@sagerx.com<br \/>\n<\/a><\/p>\n<p><b>Media Contacts<br \/>\n<\/b><br \/>Francesca Dellelci<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Francesca.Dellelci@sagerx.com\">Francesca.Dellelci@sagerx.com<br \/>\n<\/a><\/p>\n<p>Tim Lynch \/ Jed Repko<br \/>\n<br \/>Joele Frank, Wilkinson Brimmer Katcher<br \/>\n<br \/>(212) 355-4449<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical General Health Health Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250110340262\/en\/1442032\/3\/Sage_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen No Shareholder Action Required at This Time CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (Nasdaq: SAGE) (\u201cThe Company\u201d), today confirmed that Biogen Inc. (Nasdaq: BIIB) (\u201cBiogen\u201d) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders. There is no guarantee that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799691","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen No Shareholder Action Required at This Time CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (Nasdaq: SAGE) (\u201cThe Company\u201d), today confirmed that Biogen Inc. (Nasdaq: BIIB) (\u201cBiogen\u201d) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders. There is no guarantee that &hellip; Continue reading &quot;Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T23:52:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen\",\"datePublished\":\"2025-01-10T23:52:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/\"},\"wordCount\":293,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/\",\"name\":\"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-01-10T23:52:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/","og_locale":"en_US","og_type":"article","og_title":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk","og_description":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen No Shareholder Action Required at This Time CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (Nasdaq: SAGE) (\u201cThe Company\u201d), today confirmed that Biogen Inc. (Nasdaq: BIIB) (\u201cBiogen\u201d) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders. There is no guarantee that &hellip; Continue reading \"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-10T23:52:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen","datePublished":"2025-01-10T23:52:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/"},"wordCount":293,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/","name":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-01-10T23:52:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250110340262r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799691"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799691\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}